Congratulations to Dr Michael Jewett, our Past Chair, on receiving the Nicholas J. Vogelzang Humanitarian Award at #IKCSNA25! This award was named after the late co-founder of the Kidney Cancer Association, and we were honoured to be at the event where he received this prestigious recognition. (1/2)

It's great to be at #IKCSNA25 in Denver. We've met with many leaders, including Gretchen Vaughan, President & CEO of the Kidney Cancer Association, and presented a poster on the IKCC Global Patient Survey.

(Photos: Dr Eric Jonasch, Dr Michael Jewett and Gretchen Vaughan)
#KidneyCancer

"Treatment is not always about action." -- Michael Staehler, MD, PhD, of Ludwig-Maximilians University, commenting on drug holidays to reduce treatment-related side effects in #kidneycancer patients. #IKCSNA25 @kidney-cancer.bsky.social
www.medpagetoday.com/meetingcover...

A discussion about patient-centered issues in kidney cancer management focused considerable attention on the controversial antiparasitic ivermectin, which was not even on the program at #IKCSNA25. www.medpagetoday.com/meetingcover...

A majority of patients with non-locally treated brain metastases from kidney cancer remained free of metastatic progression for at least 6 months when treated with cabozantinib (Cabometyx), a small prospective study showed. #IKCSNA25
www.medpagetoday.com/meetingcover...

Patients with advanced kidney cancer treated with immune checkpoint inhibitors (ICIs) lived longer if they consumed a high-fiber diet, a small prospective study showed. #IKCSNA25
medpagetoday.com/meetingcover...

Need to catch up on #IKCSNA25?

We've got you covered. Read our reporting from @kidney-cancer.bsky.social's meeting ⬇️

An AI-based imaging analysis could serve as an aid in surgical planning for patients with kidney tumors, according to research presented at #IKCSNA25. shorturl.at/p7Z9q

A method to address discrepancies between predicted biological age and actual chronological age has been validated as a potential biomarker in predicting OS in kidney cancer, researchers report at #IKCSNA25. shorturl.at/EKpfE

An AI-based model for analyzing images is better able to predict clear cell renal cell carcinoma from CT-based images than a tumor size-based model is, suggests research from #IKCSNA25. shorturl.at/dLeIV

Current risk stratification models perform well in assessing postoperative recurrence risk in patients with non-clear cell renal cell carcinoma, according to research presented at #IKCSNA25. shorturl.at/mdL1U

After nephron-sparing ablation therapy or partial nephrectomy, RCC patients who had local recurrence had a higher mortality risk than patients without recurrence, researchers reported at #IKCSNA25. shorturl.at/YAYwX

In patients with #RCC, greater abdominal adiposity and lower skeletal mass are associated with aggressive pathology, according to research presented at #IKCSNA25. shorturl.at/etqJT

Weight loss after localized #RCC diagnosis may be a marker for disease progression and worse prognosis, researchers report at #IKCSNA25. shorturl.at/c4Flx

Long-term data show higher-stage chRCC patients have worse outcomes than those with lower-stage chRCC, oncocytoma, or ORNLMP, according to research presented at #IKCSNA25. shorturl.at/c54by

More than a quarter of patients with #RCC on active surveillance experience spontaneous tumor regression, according to research presented at #IKCSNA25. shorturl.at/R9lKl

Cabozantinib has shown efficacy in the treatment of #RCC with non-locally pretreated brain metastases, according to research presented at #IKCSNA25. shorturl.at/Yq37E